Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.31 | N/A | -8.01% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.31 | N/A | -8.01% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding the current financial landscape. They are prioritizing long-term growth despite short-term losses.
Management highlighted ongoing challenges in achieving profitability.
They emphasized a focus on strategic partnerships and research advancements.
IDEAYA Biosciences reported a loss per share that was slightly worse than expected, which may raise concerns among investors about profitability. However, the stock still rose by 1.48%, likely due to positive sentiment around their ongoing research and strategic initiatives. The lack of revenue data and guidance may leave investors cautious moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WARBY PARKER INC A
Nov 12, 2021